Abstract

Aim: The release of procalcitonin (PCT) has been suggested to be related to the type of surgery and cardiopulmonary bypass (CPB). We aimed to investigate the associations of PCT with hemodynamic stability, type of cardiac surgery, and complications.

Methods: Our study was conducted in 2015 on 76 adult patients divided into three groups according to types of surgery: group I consisted of coronary artery bypass grafting with CPB, group II consisted of cardiac valve replacement, and group III included left ventricle assist device implantation. The patients’ serum PCT values were measured preoperatively before induction, 24 and 48 hours postoperatively, and when a complication occurred.

Results: Preoperative PCT levels of the groups were similar. The PCT level in group I was lowest preoperatively, highest in postoperative 24 hours, and showed a decline postoperatively from 24 hours to 48 hours. In group II, the PCT level was increased in postoperative 24 and 48 hours compared to the preoperative level, and there was no difference between postoperative 24- and 48-hour values. In group III, the PCT level was lowest preoperatively and highest in postoperative 24 hours, while the postoperative 48-hour value was lower than the 24-hour value. Intensive care unit (ICU) stay with a higher P1PCTlevel correlated with longer ICU stay. There were no differences between patients with PCT levels ≥ 0.5 and <0.5 regarding the duration of postoperative mechanical ventilation (MV), inotropic agents, and hospitalization. Patients with higher P2PCThad a longer duration of ICU stay, postoperative MV, and hospitalization. There was a correlation between the P2PCT level and the risk of complications.

Conclusion: Increased postoperative PCT levels were associated with complications, longer durations of of hospitalization, ICU stay, and postoperative MV. We suggest that PCT might be a marker for early diagnosis of complications and follow-up of the clinical course.

Keywords: Open-heart surgery, procalcitonin, mortality, left ventricular assist device

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Deniz M, Şahin N, Aydoğdu Titiz T, Bayezid Ö. Serum procalcitonin levels in open heart surgery patients and its relationship with mortality and morbidity. Northwestern Med J. 2023;3(3):180-8. https://doi.org/10.54307/NWMJ.2023.80299

References

  1. Nardone V, Giannicola R, Bianco G, et al. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. Front Oncol. 2021; 11: 684110. https://doi.org/10.3389/fonc.2021.684110
  2. Merle C, Lepouse C, De Garine A, et al. Surgery for mesenteric infarction: prognostic factors associated with early death within 72 hours. J Cardiothorac Vasc Anesth. 2004; 18(6): 734-41. https://doi.org/10.1053/j.jvca.2004.08.011
  3. Markogiannakis H, Memos N, Messaris E, et al. Predictive value of procalcitonin for bowel ischemia and necrosis in bowel obstruction. Surgery. 2011; 149(3): 394-403. https://doi.org/10.1016/j.surg.2010.08.007
  4. Dörge H, Schöndube FA, Dörge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. Thorac Cardiovasc Surg. 2003; 51(6): 322-6. https://doi.org/10.1055/s-2003-45425
  5. Clec’h C, Fosse JP, Karoubi P, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006; 34(1): 102-7. https://doi.org/10.1097/01.ccm.0000195012.54682.f3
  6. Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999; 134(1): 49-55. https://doi.org/10.1016/s0022-2143(99)90053-7
  7. Poli EC, Alberio L, Bauer-Doerries A, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care. 2019; 23(1): 108. https://doi.org/10.1186/s13054-019-2399-4
  8. Mimoz O, Benoist JF, Edouard AR, Assicot M, Bohuon C, Samii K. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med. 1998; 24(2): 185-8. https://doi.org/10.1007/s001340050543
  9. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schüttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998; 24(7): 680-4. https://doi.org/10.1007/s001340050644
  10. Aouifi A, Piriou V, Blanc P, et al. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br J Anaesth. 1999; 83(4): 602-7. https://doi.org/10.1093/bja/83.4.602
  11. Kallel S, Abid M, Jarraya A, et al. Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery. Ann Biol Clin (Paris). 2012; 70(5): 567-80. https://doi.org/10.1684/abc.2012.0745
  12. Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med. 2000; 28(9): 3171-6. https://doi.org/10.1097/00003246-200009000-00008
  13. Meisner M, Rauschmayer C, Schmidt J, et al. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med. 2002; 28(8): 1094-102. https://doi.org/10.1007/s00134-002-1392-5
  14. Adamik B, Kübler-Kielb J, Golebiowska B, Gamian A, Kübler A. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications. Intensive Care Med. 2000; 26(9): 1259-67. https://doi.org/10.1007/s001340000610
  15. Hennig F, Stepanenko AV, Lehmkuhl HB, et al. Neurohumoral and inflammatory markers for prediction of right ventricular failure after implantation of a left ventricular assist device. Gen Thorac Cardiovasc Surg. 2011; 59(1): 19-24. https://doi.org/10.1007/s11748-010-0669-9
  16. Kettner J, Holek M, Franekova J, et al. Procalcitonin Dynamics After Long-Term Ventricular Assist Device Implantation. Heart Lung Circ. 2017; 26(6): 599-603. https://doi.org/10.1016/j.hlc.2016.09.014
  17. Loebe M, Locziewski S, Brunkhorst FM, Harke C, Hetzer R. Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery-first results of the Procalcitonin in Heart Surgery study (ProHearts). Intensive Care Med 2000; 26(2): 193-8. https://doi.org/10.1007/s001340051143
  18. Lecharny JB, Khater D, Bronchard R, et al. Hyperprocalcitonemia in patients with perioperative myocardial infarction after cardiac surgery. Crit Care Med. 2001; 29(2): 323-5. https://doi.org/10.1097/00003246-200102000-00019
  19. Minami E, Ito S, Sugiura T, Fujita Y, Sasano H, Sobue K. Markedly elevated procalcitonin in early postoperative period in pediatric open heart surgery: a prospective cohort study. J Intensive Care. 2014; 2(1): 38. https://doi.org/10.1186/2052-0492-2-38
  20. Beghetti M, Rimensberger PC, Kalangos A, Habre W, Gervaix A. Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children. Cardiol Young. 2003; 13(2): 161-7. https://doi.org/10.1017/s1047951103000301